FDA Approves Aloxi for Chemotherapy-Induced Nausea and Vomiting (CINV)

Aloxi (palonosetron) is a 5-HT3 receptor antagonist indicated for the prevention of delayed CINV caused by moderately emetogenic cancer chemotherapy.

Related Articles:

FDA Drug Approvals Archive

2010: Jan | Feb | Mar |
2009: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2004: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
2002: Aug | Oct | Dec |
(web3)